Clinical Report: Vonaprument in Phase 3 ARCHER II Trial for Geographic Atrophy
Overview
The fully enrolled phase 3 ARCHER II trial is investigating vonaprument, a monoclonal antibody fragment, for vision preservation in geographic atrophy (GA). Early phase 2 data showed good tolerability and potential efficacy, supporting further study in a larger patient population.
Background
Geographic atrophy is a progressive form of age-related macular degeneration characterized by irreversible vision loss. Currently, there are no approved treatments that effectively preserve vision in GA. Vonaprument (formerly ANX007) is designed to target pathways involved in GA progression and is being evaluated for its ability to slow vision loss. The ARCHER II trial aims to confirm these effects with a global pathway to registration based on vision preservation endpoints.
Data Highlights
The ARCHER II trial is a fully enrolled phase 3 study evaluating vonaprument in patients with GA. The primary endpoint is the event of a 15-letter vision loss, with the hypothesis that vonaprument reduces the rate of such vision loss compared to control. Inclusion criteria mirror those of the successful phase 2 study, which demonstrated good safety and tolerability.
Key Findings
- ARCHER II is a fully enrolled phase 3 trial assessing vonaprument in geographic atrophy.
- The primary endpoint is vision preservation, defined as preventing a 15-letter loss in visual acuity.
- Inclusion criteria are consistent with the phase 2 study, enhancing the likelihood of a positive phase 3 outcome.
- Phase 2 data showed vonaprument was well tolerated with promising efficacy signals.
- Vonaprument is a monoclonal antibody fragment based on ranibizumab, suggesting a favorable safety profile.
Clinical Implications
If successful, vonaprument could become the first therapy to preserve vision in patients with geographic atrophy, addressing a significant unmet need. The trial's design and prior safety data support its potential for regulatory approval and clinical adoption. Clinicians should monitor ongoing results to inform future treatment strategies for GA.
Conclusion
The ARCHER II trial represents a pivotal step toward a novel treatment option for geographic atrophy, with vonaprument showing promise in preserving vision. Continued evaluation will determine its role in clinical practice.
References
- Eichenbaum DE, Do D -- ASRS 2025: Rationale and Progress of ARCHER II Trial of Vonaprument in GA
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.